Eurofins Consolidates Its Market Leadership in Environment Testing in Finland with the Acquisition of Ahma Group
April 04 2017 - 7:17AM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), the global leader in
food and environment testing, announces that it has acquired Ahma
Ymparisto Oy (“Ahma”), the second-largest environment testing
laboratory in Finland.
Founded in 1977, Ahma has built a solid reputation in the
domestic environment testing market, with a strong footprint in the
northern and western parts of the country, and with some strong
competences in the fields of water, hydrobiology and bio-fuels
testing in particular. The company employs 104 staff across its 3
main sites, and generated revenues in excess of EUR 7m in 2016.
Ahma’s geographical footprint and test portfolio complements the
Group’s strong presence in the south of the country, obtained
following the recent acquisition of Ramboll Group’s laboratories.
The acquisition should therefore consolidate the Group’s leadership
in the Finnish environment testing market.
Comment from Antti Kuivalainen, Chairman of the Board of
Ahma Insin��rit Oy: “I am very proud that Ahma Environment found a
new home within the Eurofins family. This transaction will create a
superior environmental testing and research organisation in Finland
as well as in the whole Nordics.”
Comment from Dr. Gilles Martin, Eurofins CEO: “The
acquisition of Ahma illustrates Eurofins’ strategy of consolidating
and continually strengthening our leading operational footprint. We
are committed to supporting Ahma’s further development by giving
them access to the full range of capabilities of the Group.
Together with the recently-acquired laboratories from Ramboll, we
look forward to supporting their respective operations and further
developing their capabilities to continue providing customers in
Finland with the highest level of analytical service.”
For more information, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 27,000
staff in 310 laboratories across 39 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170404005753/en/
Investor RelationsEurofins ScientificPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Apr 2023 to Apr 2024